INS and Hypoglycemia: Finally, a role was suggested for closed-loop glucose control systems and immunomodulatory treatment options, to avoid hypoglycemia during insulin therapy and to control the rise in circulating cytokine levels in diabetic patients with severe sepsis and septic shock [60].